Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

bioAffinity Technologies (BIAF) Operating Expenses: 2022-2025

Historic Operating Expenses for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to $3.7 million.

  • bioAffinity Technologies' Operating Expenses fell 13.54% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.2 million, marking a year-over-year decrease of 3.15%. This contributed to the annual value of $18.3 million for FY2024, which is 74.34% up from last year.
  • Per bioAffinity Technologies' latest filing, its Operating Expenses stood at $3.7 million for Q3 2025, which was down 1.22% from $3.8 million recorded in Q2 2025.
  • Over the past 5 years, bioAffinity Technologies' Operating Expenses peaked at $5.2 million during Q4 2024, and registered a low of $685,279 during Q2 2022.
  • Its 3-year average for Operating Expenses is $3.7 million, with a median of $4.3 million in 2024.
  • Its Operating Expenses has fluctuated over the past 5 years, first spiked by 180.12% in 2023, then declined by 15.62% in 2025.
  • Quarterly analysis of 4 years shows bioAffinity Technologies' Operating Expenses stood at $1.6 million in 2022, then skyrocketed by 180.12% to $4.6 million in 2023, then grew by 13.13% to $5.2 million in 2024, then declined by 13.54% to $3.7 million in 2025.
  • Its Operating Expenses was $3.7 million in Q3 2025, compared to $3.8 million in Q2 2025 and $4.5 million in Q1 2025.